The UVA-LEWWIN Innovative Drug Research and Molecular Imaging Technology and Product Research Platform is co-founded by Lewwin Pharm and the University of Virginia. The platform is dedicated to strengthening collaboration in innovative drug research and molecular imaging technology and product development. Based on the principles of complementary advantages and mutual benefit, the two parties have established a long-term strategic alliance to facilitate the global translation of research outcomes.
The platform is currently conducting research on one Class 1 chemical diagnostic drug, one peptide drug for preventing corneal transplant rejection, and screening studies on peptide drugs for combating the COVID-19 “cytokine storm”, with the aim of discovering peptides that can prevent and treat inflammatory storms.
